ASX & MEDIA RELEASE
2 NOVEMBER, 2010

NOVOGEN APPOINTS NEW DIRECTOR

Sydney, Australia - Pharmaceutical development company, Novogen Limited (ASX: NRT, NASDAQ: NVGN), has appointed a new Director.

Mr Peter Scutt, an Australian based corporate advisor, joins the Board immediately.

Mr Scutt is currently a consultant to specialist corporate advisory and investment house, Spark Capital. He brings broad investment and corporate finance experience to Novogen through his past positions at Texel Capital and BT Venture Partners. His early career was highlighted by senior positions at Bankers Trust Co both in Australia and New York.

Novogen Chairman, Mr Bill Rueckert said, "We are very pleased that Peter has joined the Board of Novogen. As we continue to structure and explore opportunities for the Company, Peter's experience and expertise will be invaluable. We look forward to his participation in our activities."

About Novogen

Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen has a consumer healthcare business, provides research and development services to its 71.3 per cent owned subsidiary, Marshall Edwards, Inc., in relation to oncology therapeutics and is developing glucan technology through its 80.7 per cent owned subsidiary, Glycotex, Inc.

ISSUED FOR	**:**	**NOVOGEN LIMITED**
LISTINGS	**:**	**ASX (CODE NRT), NASDAQ (CODE NVGN).**
FOR FURTHER INFORMATION	**:**	**MR BILL RUECKERT, CHAIRMAN, NOVOGEN LIMITED** **TEL (02) 9878 0088 http://www.novogen.com**
ISSUED BY	**:**	**WESTBROOK COMMUNICATIONS** **CONTACT: IAN WESTBROOK TEL (02) 9231 0922, 0407 958 137**